Microfluidic nanochips for rapid exosome isolation and multiplex biomarker profiling from a single blood drop: Toward sample-to-answer liquid biopsy
Daniel Ejim Uti , Esther Ugo Alum , Josephine E. Egbung , Waheeb Sami Aggad , Hailah M. Almohaimeed , Zuhair M. Mohammedsaleh , Manpreet Kaur , Kranti Kiran Reddy Ealla
Clinical and Translational Discovery ›› 2026, Vol. 6 ›› Issue (4) : e70170
Background: Exosomes and other small extracellular vesicles carry molecular cargo that can reflect disease status, therapeutic response, and relapse dynamics. Currently, most exosome-analysis workflows are centralized, require milliliter-sized blood samples, involve extended isolation procedures, and depend on separate downstream assays. Single-drop microfluidic nanochips, which can process finger-prick blood volumes of approximately 1050 µL within a closed cartridge, offer a promising route toward integrated sample-to-answer liquid biopsy platforms.
Main Body: These systems may integrate plasma handling, exosome enrichment, cargo access, multiplex biomarker detection, and algorithmic classification. This review highlights key on-chip enrichment techniques, including immunoaffinity, size selection, electrokinetic, acoustofluidic, and hybrid methods. It also discusses nano-biointerface designs that improve vesicle capture efficiency while reducing fouling and shear-induced vesicle damage. In addition, multiplex sensing architectures for optical, electrochemical, and plasmonic transduction are explored, with particular attention to challenges associated with whole-blood measurements, including anticoagulation, sample variability, platelet activation, viscosity, and hemolysis.
Conclusions: Single-drop exosome nanochips have the potential to transform liquid biopsy by enabling rapid, low-volume, integrated analysis of extracellular vesicles. However, successful clinical translation will require clear validation requirements, standardized reporting expectations, and defined use-case roadmaps for screening, disease monitoring, and therapeutic-response assessment. Establishing realistic performance standards and robust engineering parameters will be essential for making single-lab exosome nanochip platforms reproducible and clinically applicable.
exosomes / extracellular vesicles / liquid biopsy / microfluidics / multiplex biosensing / nanochips / point-of-care diagnostics
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
Lina. Microfluidic Prototyping for Scalable Manufacturing | Micromolds. https://www.micromolds.eu/post/microfluidic-prototyping-for-scalable-manufacturing |
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
2026 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |